Drugs that contain Bromfenac Sodium
1. Bromsite patents expiration
Can you believe BROMSITE received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8778999 | SUN PHARM | Non-steroidal anti-inflammatory ophthalmic compositions |
Aug, 2029
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 08, 2019 |
Market Authorisation Date: 08 April, 2016
Treatment: Treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery
Dosage: SOLUTION/DROPS;OPHTHALMIC
How can I launch a generic of BROMSITE before it's drug patent expiration?
More Information on Dosage
BROMSITE family patents
2. Prolensa patents expiration
PROLENSA's oppositions filed in EPO
PROLENSA Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8129431 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Sep, 2025
(1 year, 4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8754131 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(3 months ago) | |
| US9561277 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(3 months ago) | |
| US8927606 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(3 months ago) | |
| US9144609 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(3 months ago) | |
| US8669290 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(3 months ago) | |
| US8871813 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(3 months ago) | |
| US10085958 | BAUSCH AND LOMB | Bromfenac bioavailability |
Nov, 2032
(8 years from now) | |
| US9517220 | BAUSCH AND LOMB | Bromfenac bioavailability |
Nov, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 05, 2016 |
Market Authorisation Date: 05 April, 2013
Treatment: Treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery; Method of treating ocular inflammation
Dosage: SOLUTION/DROPS;OPHTHALMIC
How can I launch a generic of PROLENSA before it's drug patent expiration?
More Information on Dosage
PROLENSA family patents